Brain and Central Nervous System Tumors

Oncology
18
Pipeline Programs
10
Companies
22
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
2
7
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
233%
Monoclonal Antibody
233%
Vaccine
117%
Small Molecule
117%
+ 12 programs with unclassified modality

On Market (1)

Approved therapies currently available

M&
TEMODARApproved
temozolomide
Merck & Co.
Alkylating Drug [EPC]intravenous2009

Competitive Landscape

10 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
1
temozolomidePhase 31 trial
Active Trials
NCT00626990Active Not Recruiting751Est. Dec 2029
Alliance Pharmaceuticals
6 programs
1
4
bevacizumabPhase 2Monoclonal Antibody1 trial
carmustinePhase 21 trial
carmustinePhase 22 trials
irinotecan hydrochloridePhase 21 trial
everolimusPhase 1/21 trial
+1 more programs
Active Trials
NCT00003863Completed391Est. May 2005
NCT01004523Completed135Est. Mar 2013
NCT00553150Completed122Est. Nov 2019
+5 more trials
Knight Therapeutics
Knight TherapeuticsQC - Montréal
3 programs
1
1
1
RituxanPhase 21 trial
trastuzumabPhase 1/2Monoclonal Antibody1 trial
MelphalanPhase 11 trial
Active Trials
NCT00253721Terminated21Est. Dec 2016
NCT00397501Withdrawn0Est. Oct 2013
NCT00074165Terminated17Est. Dec 2010
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
vatalanibPhase 2Small Molecule1 trial
yttrium Y 90-edotreotidePhase 1Peptide1 trial
Active Trials
NCT00006368Completed60Est. Nov 2003
NCT00348790Completed25Est. Jul 2013
Bristol Myers Squibb
1 program
1
CT-322Phase 23 trials
Active Trials
NCT01146171Withdrawn0Est. Jan 2015
NCT00562419Unknown72Est. Dec 2011
NCT00374179Completed40Est. Feb 2009
Kazia Therapeutics
Kazia TherapeuticsAustralia - Sydney
1 program
1
GDC-0084Phase 11 trial
Active Trials
NCT03696355CompletedEst. Sep 2022
PTC Therapeutics
1 program
1
VEGF inhibitor PTC299Phase 11 trial
Active Trials
NCT01158300Completed28Est. Jan 2015
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
cilengitidePhase 1Peptide1 trial
Active Trials
NCT00884598Completed19Est. Oct 2012
IB
Immatics BiotechnologiesGermany - Munich
1 program
1
glioblastoma multiforme multipeptide vaccine IMA950Phase 1Vaccine1 trial
Active Trials
NCT01222221Completed45Est. Feb 2015
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
therapeutic autologous lymphocytesPhase 11 trial
Active Trials
NCT00730613CompletedEst. Aug 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Merck & Co.temozolomide
Alliance Pharmaceuticalsbevacizumab
Bristol Myers SquibbCT-322
Novartisvatalanib
Knight TherapeuticsRituxan
Alliance Pharmaceuticalscarmustine
Alliance Pharmaceuticalscarmustine
Alliance Pharmaceuticalscarmustine
Alliance Pharmaceuticalsirinotecan hydrochloride
Knight Therapeuticstrastuzumab
Alliance Pharmaceuticalseverolimus
Kazia TherapeuticsGDC-0084
Bristol Myers SquibbCT-322
PTC TherapeuticsVEGF inhibitor PTC299
Immatics Biotechnologiesglioblastoma multiforme multipeptide vaccine IMA950

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 1,970 patients across 22 trials

NCT00626990Merck & Co.temozolomide

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Start: Dec 2007Est. completion: Dec 2029751 patients
Phase 3Active Not Recruiting
NCT00621686Alliance Pharmaceuticalsbevacizumab

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Start: Sep 2008Est. completion: Feb 201454 patients
Phase 2Completed
NCT00562419Bristol Myers SquibbCT-322

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Start: Oct 2007Est. completion: Dec 201172 patients
Phase 2Unknown
NCT00348790Novartisvatalanib

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Start: May 2006Est. completion: Jul 201325 patients
Phase 2Completed
NCT00074165Knight TherapeuticsRituxan

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Start: Jan 2003Est. completion: Dec 201017 patients
Phase 2Terminated
NCT00006747Alliance Pharmaceuticalscarmustine

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Start: Nov 2000Est. completion: Feb 20034 patients
Phase 2Completed
NCT00003996Alliance Pharmaceuticalscarmustine

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Start: May 1999Est. completion: May 200893 patients
Phase 2Completed
NCT00003621Alliance Pharmaceuticalscarmustine

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma

Start: Feb 1999Est. completion: Jul 200529 patients
Phase 2Completed
NCT00003134Alliance Pharmaceuticalsirinotecan hydrochloride

Irinotecan in Treating Patients With Recurrent Glioma

Start: Jan 1998Est. completion: Jan 200964 patients
Phase 2Completed
NCT00397501Knight Therapeuticstrastuzumab

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Start: Oct 2013Est. completion: Oct 20130
Phase 1/2Withdrawn
NCT00553150Alliance Pharmaceuticalseverolimus

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Start: Mar 2009Est. completion: Nov 2019122 patients
Phase 1/2Completed
NCT03696355Kazia TherapeuticsGDC-0084

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

Start: Nov 2018Est. completion: Sep 2022
Phase 1Completed
NCT01146171Bristol Myers SquibbCT-322

Japanese Phase 1 Study of BMS-844203 (CT322)

Start: Nov 2013Est. completion: Jan 20150
Phase 1Withdrawn
NCT01158300PTC TherapeuticsVEGF inhibitor PTC299

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

Start: Nov 2010Est. completion: Jan 201528 patients
Phase 1Completed
NCT01222221Immatics Biotechnologiesglioblastoma multiforme multipeptide vaccine IMA950

Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Start: Jul 2010Est. completion: Feb 201545 patients
Phase 1Completed
NCT00884598Heidelberg Pharmacilengitide

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

Start: Dec 2008Est. completion: Oct 201219 patients
Phase 1Completed
NCT00374179Bristol Myers SquibbCT-322

CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Start: Aug 2006Est. completion: Feb 200940 patients
Phase 1Completed
NCT00730613City Therapeuticstherapeutic autologous lymphocytes

Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma

Start: Feb 2002Est. completion: Aug 2011
Phase 1Completed
NCT00253721Knight TherapeuticsMelphalan

Melphalan With BBBD in Treating Patients With Brain Malignancies

Start: May 1998Est. completion: Dec 201621 patients
Phase 1Terminated
NCT00006368Novartisyttrium Y 90-edotreotide

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Start: Jan 1998Est. completion: Nov 200360 patients
Phase 1Completed
NCT00003863Alliance Pharmaceuticalsfluorescence in situ hybridization

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Start: Jun 1999Est. completion: May 2005391 patients
N/ACompleted
NCT01004523Alliance Pharmaceuticalsfluorescence in situ hybridization

Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

Start: Dec 1995Est. completion: Mar 2013135 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4m ago

Office Administrator

SystImmune
4m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
18m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
18m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)